检索范围:
排序: 展示方式:
Natural killer cells in liver diseases
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 269-279 doi: 10.1007/s11684-018-0621-4
The liver has been characterized as a frontline lymphoid organ with complex immunological features such as liver immunity and liver tolerance. Liver tolerance plays an important role in liver diseases including acute inflammation, chronic infection, autoimmune disease, and tumors. The liver contains a large proportion of natural killer (NK) cells, which exhibit heterogeneity in phenotypic and functional characteristics. NK cell activation, well known for its role in the immune surveillance against tumor and pathogen-infected cells, depends on the balance between numerous activating and inhibitory signals. In addition to the innate direct “killer” functions, NK cell activity contributes to regulate innate and adaptive immunity (helper or regulator). Under the setting of liver diseases, NK cells are of great importance for stimulating or inhibiting immune responses, leading to either immune activation or immune tolerance. Here, we focus on the relationship between NK cell biology, such as their phenotypic features and functional diversity, and liver diseases.
关键词: natural killer cell phenotype immune activation immune tolerance liver diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1017-7
关键词: single-cell RNA-seq glioma radial glia primitive oligodendrocyte precursor cell immune escape
《医学前沿(英文)》 2023年 第17卷 第1期 页码 18-42 doi: 10.1007/s11684-022-0976-4
关键词: non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint inhibitors
Immunometabolism: a new dimension in immunotherapy resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 585-616 doi: 10.1007/s11684-023-1012-z
关键词: immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor
《医学前沿(英文)》 2022年 第16卷 第4期 页码 596-609 doi: 10.1007/s11684-021-0868-z
关键词: innate immune checkpoint Siglec10 kidney renal clear cell carcinoma
Mesenchymal stem cells and immune disorders: from basic science to clinical transition
Shihua Wang, Rongjia Zhu, Hongling Li, Jing Li, Qin Han, Robert Chunhua Zhao
《医学前沿(英文)》 2019年 第13卷 第2期 页码 138-151 doi: 10.1007/s11684-018-0627-y
关键词: mesenchymal stem cell clinical transition immune disorders
Challenges of NK cell-based immunotherapy in the new era
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 440-450 doi: tzg@ustc.edu.cn
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
关键词: natural killer cells immunotherapy adoptive transfer genetic modification immune checkpoint inhibitor
免疫调节细胞生物学及其在急性移植物抗宿主病预防或治疗中的临床应用 Review
Bruce R. Blazar
《工程(英文)》 2019年 第5卷 第1期 页码 98-105 doi: 10.1016/j.eng.2018.11.016
预防和治疗移植物抗宿主病(GVHD)最常见的方法是尝试耗竭或抑制能介导或支持同种异体反应的T细胞;但这会导致T细胞受体功能缺陷,并因此对感染和肿瘤复发高度敏感。通常通过广泛使用反应性抗体来实现耗竭,而功能损坏通常在使用需长期给药(一般为6个月或更长时间)且具有明显副作用的药物后发生,这种药物可能不会导致供体T细胞对耐调节方案且携带宿主同种抗原的细胞产生耐受性(即无反应性)。随着对免疫系统稳态认识的深化,我们已能鉴定和表征具有免疫调节功能的细胞群。虽然这种细胞群通常比较少见,但可通过分离和扩增此类细胞的方法在移植后晚期增补供体移植物或进行输注,来抑制GVHD。本文将探讨GVHD模型中的生物学和临床前概念验证,以及现已发展至临床测试阶段的免疫调节细胞疗法对GVHD的疗效。
关键词: 移植物抗宿主病(GVHD) 免疫调节细胞 细胞疗法
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 153-163 doi: 10.1007/s11684-017-0548-1
To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution (IR) in 144 patients who received allogeneic stem cell transplantation (allo-SCT) and without showing any of the following events: poor graft function, grades II?IV acute graft-versus-host disease (GVHD), serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3+ T cells, CD8+ T cells, and CD19+ B cells, and very slow in CD4+ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune cells need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune cell counts in patients receiving HSCT.
关键词: immune reconstitution hematopoietic stem cell transplantation event-free patients reference range
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
《医学前沿(英文)》 2021年 第15卷 第1期 页码 33-42 doi: 10.1007/s11684-019-0735-3
关键词: cancer immunotherapy immune checkpoint inhibitors immune-related adverse events review
Tangchun Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 816-819 doi: 10.1007/s11684-020-0823-4
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
null
《医学前沿(英文)》 2014年 第8卷 第1期 页码 1-5 doi: 10.1007/s11684-014-0309-3
Hyperthermia is a condition characterized by increased body temperature as a consequence of failed thermoregulation. Hyperthermia occurs when a body produces or absorbs more heat than it dissipates. Hyperthermia also elicits various effects on the physiology of living cells. For instance, fever-range temperature (39β°C to 40β°C) can modulate the activities of immune cells, including antigen-presenting cells, T cells, and natural killer cells. Heat shock temperature (41β°C to 43β°C) can increase the immunogenicity of tumor cells. Cytotoxic temperature (>43β°C) can create an antigen source to induce an anti-tumor immune response. The immunomodulatory effect of hyperthermia has promoted an interest in hyperthermia-aided immunotherapy, particularly against tumors. Hyperthermia has also been used to treat deep fungal, bacterial, and viral skin infections. We conducted a series of open or controlled trials to treat skin human papillomavirus infection by inducing local hyperthermia. More than half of the patients were significantly cured compared with those in the control trial. A series of challenging clinical cases, such as large lesions in pregnant patients or patients with diabetes mellitus, were also successfully and safely managed using the proposed method. However, further studies should be conducted to clarify the underlying mechanisms and promote the clinical applications of hyperthermia.
标题 作者 时间 类型 操作
Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell
期刊论文
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future
期刊论文
Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient
期刊论文
Mesenchymal stem cells and immune disorders: from basic science to clinical transition
Shihua Wang, Rongjia Zhu, Hongling Li, Jing Li, Qin Han, Robert Chunhua Zhao
期刊论文
Comparison of reference values for immune recovery between event-free patients receiving haploidentical
null
期刊论文
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
期刊论文
Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
Tangchun Wu
期刊论文